InsiderTrades

Form 4 for CCCC C4 Therapeutics, Inc.

Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-13 · accession 0001470831-26-000180 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2026-02-18 2026-02-13+ CCCC Boyle Scott N Chief Business Off F - Tax $1.89 -9,004 306.1K -3% -$17.0K
M 2026-02-18 2026-02-13+ CCCC Boyle Scott N Chief Business Off M - OptEx $0.00 +25.9K 307.8K +9% $0
2026-02-18 2026-02-13 CCCC Boyle Scott N Chief Business Off A - Grant $0.00 +200.0K 307.8K +186% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-14 F D 7,269 $1.89 298,801 D — —
2 Common Common Stock 2026-02-14 M A 20,950 $0.00 306,070 D — —
3 Common Common Stock 2026-02-13 A A 200,000 $0.00 307,805 D — — (F1) Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
4 Common Common Stock 2026-02-13 M A 5,000 $0.00 307,805 D — —
5 Common Common Stock 2026-02-13 F D 1,735 $1.89 306,070 D — —